Why radiopharma Pentixapharm chose Frankfurt for IPO
Eckert & Ziegler spinout aiming for 4Q24 debut with secondary listing as future option
Why is a therapeutics company in one of the hottest spaces in biotech choosing to go public on the Frankfurt stock exchange and not NASDAQ? It’s because the company doesn’t really have a choice — at least, not yet.
German radioisotope provider Eckert & Ziegler SE (Xetra:EUZ) announced last week that it is spinning out its radiopharma therapeutics and diagnostics subsidiary Pentixapharm Holding AG, with plans for the company to list on the Frankfurt Stock Exchange next quarter. ...
BCIQ Company Profiles